NCT03128320View on ClinicalTrials.gov

The Effects of BAY1193397 on Skin Capillary Blood Flow and Transcutaneous Oxygen Pressure

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

May 25, 2017

Primary Completion Date

September 6, 2019

Study Completion Date

October 28, 2019

Conditions
Diabetic Foot
Interventions
DRUG

BAY1193397

Single dose of 1 mg BAY1193397 given in the fasted state

DRUG

BAY1193397

Single dose of 5 mg BAY1193397 given in the fasted state

DRUG

Placebo

Single dose of placebo given in the fasted state

Trial Locations (1)

EX2 5AX

Royal Devon & Exeter Hospital, Exeter

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT03128320 - The Effects of BAY1193397 on Skin Capillary Blood Flow and Transcutaneous Oxygen Pressure | Biotech Hunter | Biotech Hunter